Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Lipid-based nanoformulations for peptide delivery
Inserm, France.
RISE, SP – Sveriges Tekniska Forskningsinstitut, SP Kemi Material och Ytor, Life Science.ORCID iD: 0000-0003-4742-1702
Inserm, France.
Inserm, France.
Show others and affiliations
2016 (English)In: International Journal of Pharmaceutics, ISSN 0378-5173, E-ISSN 1873-3476, Vol. 502, no 1-2, p. 80-97Article, review/survey (Refereed) Published
Resource type
Text
Abstract [en]

Nanoformulations have attracted a lot of attention because of their size-dependent properties. Among the array of nanoformulations, lipid nanoformulations (LNFs) have evoked increasing interest because of the advantages of their high degree of biocompatibility and versatility. The performance of lipid nanoformulations is greatly influenced by their composition and structure. Therapeutic peptides represent a growing share of the pharmaceutical market. However, the main challenge for their development into commercial products is their inherent physicochemical and biological instability. Important peptides such as insulin, calcitonin and cyclosporin A have been incorporated into LNFs. The association or encapsulation of peptides within lipid-based carriers has shown to protect the labile molecules against enzymatic degradation. This review describes strategies used for the formulation of peptides and some methods used for the assessment of association efficiency. The advantages and drawbacks of such carriers are also described.

Place, publisher, year, edition, pages
Elsevier, 2016. Vol. 502, no 1-2, p. 80-97
Keywords [en]
Drug delivery, Lipids, Nanoformulations, Peptides
National Category
Other Chemistry Topics Physical Chemistry Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:ri:diva-90DOI: 10.1016/j.ijpharm.2016.02.019Scopus ID: 2-s2.0-84959179307OAI: oai:DiVA.org:ri-90DiVA, id: diva2:930616
Available from: 2016-05-24 Created: 2016-04-28 Last updated: 2019-06-17Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textScopus

Authority records BETA

Boge, LukasBysell, Helena

Search in DiVA

By author/editor
Boge, LukasBysell, Helena
By organisation
Life Science
In the same journal
International Journal of Pharmaceutics
Other Chemistry TopicsPhysical ChemistryPharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 47 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
v. 2.35.9